Dallas, TX - September 28, 2022 - Stonegate Healthcare will host a virtual investor event with ophthalmology experts to discuss Retinitis Pigmentosa (RP) and the pipeline of products in development. Participants will include Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., CDO of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman from the Foundation Fighting Blindness. The 30 minute event will be held Wednesday, October 19, 2022 at 4:30 PM Eastern Time.
“At Stonegate we are focused on highlighting innovations in healthcare that can revolutionize the treatment of diseases with high unmet need," said Shiv Kapoor, Managing Partner Healthcare at Stonegate Capital Partners and moderator of the virtual investor event. "We look forward to learning more about innovative treatments for Retinitis Pigmentosa which have the potential to usher in a new era for patients with few options.”
Webinar Title: Battling Blindness in Retinitis Pigmentosa: A Discussion of Disease & the Pipeline of Hope
Description: Retinitis pigmentosa is a rare, inherited genetic eye disease that causes severe loss of functional vision due to degeneration of the retinal photoreceptors, the light-sensing cells. To date, there is no cure for retinitis pigmentosa.
This webinar will provide an overview of the disease progression from diagnosis to blindness, and how patients’ lives are affected. More specifically, the panel of RP experts will discuss the landscape of investigational treatments with technologies ranging from gene and cell therapies to photoresponsive small molecules, including the patient, medical and industry perspectives.
Location & Time: Click here to join live on October 19, 2022 04:30 PM Eastern Time. A replay of the presentation will be available on the IR section of Kiora's website.